m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00298)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
ITGB1
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Fat mass and obesity-associated protein (FTO) [ERASER]
Representative RNA-seq result indicating the expression of this target gene regulated by FTO | ||
Cell Line | 253J cell line | Homo sapiens |
Treatment: siFTO 253J cells
Control: 253J cells
|
GSE150239 | |
Regulation |
|
logFC: 6.90E-01 p-value: 1.74E-07 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | FTO was an independent risk factor for overall survival (OS) of GC patients and FTO could promote GC metastasis by upregulating the expression of Integrin beta-1 (ITGB1) via decreasing its m6A level. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Gastric cancer | ICD-11: 2B72 | ||
In-vitro Model | SNU-216 | Gastric tubular adenocarcinoma | Homo sapiens | CVCL_3946 |
MKN7 | Gastric tubular adenocarcinoma | Homo sapiens | CVCL_1417 | |
MGC-803 | Gastric mucinous adenocarcinoma | Homo sapiens | CVCL_5334 | |
HGC-27 | Gastric carcinoma | Homo sapiens | CVCL_1279 | |
BGC-823 | Gastric carcinoma | Homo sapiens | CVCL_3360 | |
AGS | Gastric adenocarcinoma | Homo sapiens | CVCL_0139 | |
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | LX2 cell line | Homo sapiens |
Treatment: shMETTL3 LX2 cells
Control: shLuc LX2 cells
|
GSE207909 | |
Regulation |
|
logFC: -2.05E+00 p-value: 1.83E-215 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | METTL3 regulates the expression of Integrin beta-1 (ITGB1) through m6A-HuR-dependent mechanism, which affects the binding of ITGB1 to Collagen I and tumor cell motility, so as to promote the bone metastasis of prostate cancer. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Prostate cancer | ICD-11: 2C82 | ||
Pathway Response | Cell adhesion molecules | hsa04514 | ||
Cell Process | Cell adhesion | |||
In-vitro Model | LNCaP | Prostate carcinoma | Homo sapiens | CVCL_0395 |
PC-3 | Prostate carcinoma | Homo sapiens | CVCL_0035 | |
In-vivo Model | All the mice were randomly divided into five groups of four mice each, including PC3-shNC, PC3-shMETTL3-1/2, LNCaP-vector and LNCaP-METTL3 group. | |||
YTH domain-containing family protein 2 (YTHDF2) [READER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | KAT1 triggers YTHDF2-mediated Integrin beta-1 (ITGB1) mRNA instability to alleviate the progression of DR. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Diabetic retinopathy | ICD-11: 9B71.0 | ||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
Cell Process | RNA stability | |||
In-vitro Model | RMECs (Retinal microvascular endothelial cells (RMECs) purchased from Olaf (Worcester, MA, USA)) | |||
rMCs (Retinal Muller cells (rMCs) from Kerafast Inc. (Boston, MA)) | ||||
In-vivo Model | Male mice (8-10 weeks old, SLAC Laboratory Animal Co., Ltd., Shanghai, China) were administrated with STZ through intraperitoneal injection (I.P) for continuous 5 days (d). | |||
Gastric cancer [ICD-11: 2B72]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | FTO was an independent risk factor for overall survival (OS) of GC patients and FTO could promote GC metastasis by upregulating the expression of Integrin beta-1 (ITGB1) via decreasing its m6A level. | |||
Responsed Disease | Gastric cancer [ICD-11: 2B72] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
In-vitro Model | SNU-216 | Gastric tubular adenocarcinoma | Homo sapiens | CVCL_3946 |
MKN7 | Gastric tubular adenocarcinoma | Homo sapiens | CVCL_1417 | |
MGC-803 | Gastric mucinous adenocarcinoma | Homo sapiens | CVCL_5334 | |
HGC-27 | Gastric carcinoma | Homo sapiens | CVCL_1279 | |
BGC-823 | Gastric carcinoma | Homo sapiens | CVCL_3360 | |
AGS | Gastric adenocarcinoma | Homo sapiens | CVCL_0139 | |
Lung cancer [ICD-11: 2C25]
Prostate cancer [ICD-11: 2C82]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | METTL3 regulates the expression of Integrin beta-1 (ITGB1) through m6A-HuR-dependent mechanism, which affects the binding of ITGB1 to Collagen I and tumor cell motility, so as to promote the bone metastasis of prostate cancer. | |||
Responsed Disease | Prostate cancer [ICD-11: 2C82] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Cell adhesion molecules | hsa04514 | ||
Cell Process | Cell adhesion | |||
In-vitro Model | LNCaP | Prostate carcinoma | Homo sapiens | CVCL_0395 |
PC-3 | Prostate carcinoma | Homo sapiens | CVCL_0035 | |
In-vivo Model | All the mice were randomly divided into five groups of four mice each, including PC3-shNC, PC3-shMETTL3-1/2, LNCaP-vector and LNCaP-METTL3 group. | |||
Retinopathy [ICD-11: 9B71]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | KAT1 triggers YTHDF2-mediated Integrin beta-1 (ITGB1) mRNA instability to alleviate the progression of DR. | |||
Responsed Disease | Diabetic retinopathy [ICD-11: 9B71.0] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
Cell Process | RNA stability | |||
In-vitro Model | RMECs (Retinal microvascular endothelial cells (RMECs) purchased from Olaf (Worcester, MA, USA)) | |||
rMCs (Retinal Muller cells (rMCs) from Kerafast Inc. (Boston, MA)) | ||||
In-vivo Model | Male mice (8-10 weeks old, SLAC Laboratory Animal Co., Ltd., Shanghai, China) were administrated with STZ through intraperitoneal injection (I.P) for continuous 5 days (d). | |||
References